Symbols

CCCC

C4 Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CCCC

C4 Therapeutics, Inc.

A developer of novel therapies for cancer and other diseases using its proprietary Cell Selection and Engineering (CSE) platform

Industry

Biological Technology

Established Date

10/07/2015

Listing Date

10/02/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

104

Fiscal Year Ends

12-31

Website

www.c4therapeutics.com

Security Type

Common stock

Office address

490 Arsenal Way Suite 120 Watertown MA 02472

Business

Introduction

C4 Therapeutics, Inc., was incorporated in Delaware on October 7, 2015. The company is a biopharmaceutical company dedicated to harnessing the body's natural regulation of protein levels to develop new therapeutic drug candidates to target and destroy disease-causing proteins to treat cancer, neurodegenerative diseases and other diseases.

Company Financials

EPS

CCCC has released its 2025 Q4 earnings. EPS was reported at -0.18, versus the expected -0.29, beating expectations. The chart below visualizes how CCCC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CCCC has released its 2025 Q4 earnings report, with revenue of 11.02M, reflecting a YoY change of 112.79%, and net profit of -20.49M, showing a YoY change of 40.75%. The Sankey diagram below clearly presents CCCC's revenue sources and cost distribution.